-
Availability and costs of medicines for the treatment of tuberculosis in Europe [Elektronski vir]Günther, Gunar ...Objectives. To evaluate the access to comprehensive diagnostics and novel anti-tuberculosis medicines in European countries. Methods. We investigated access to genotypic and phenotypic M. ... tuberculosis drug susceptibility testing, availability of anti-tuberculosis drugs and calculated cost of drugs and treatment regimens at major tuberculosis treatment centers in countries of the World Health Organization (WHO) European region where rates of drug-resistant tuberculosis are highest among all WHO regions. Results are stratified by middle-income and high-income countries. Results. Overall, 43 treatment centers in 43 countries participated in the study. For WHO Group A drugs, the frequency of countries with availability of phenotypic drug susceptibility testing was as follows: 30/40 (75%) for levofloxacin, 33/40 (82%) for moxifloxacin, 19/40 (48%) for bedaquiline and 29/40 (72%) for linezolid, respectively. Overall, 36/43 (84%) and 24/43 (56%) of countries had access to bedaquiline and delamanid, while only 6/43 (14%) had access to rifapentine. Treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was only available in 17/43 (40%) of the countries. Median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for six months) and extensively drug-resistant tuberculosis (including bedaquiline, delamanid and a carbapenem) were € 44 (min-max € 15-152), € 764 (min-max € 542-15152) and € 8709 (min-max € 7965-11759) in middle-income countries (n=12), and € 280 (min-max-€78-1084), € 29765 (min-max 11116-40584), € 217591 (min-max € 82827-320146) in high-income countries (n=29). Conclusion. In countries of the WHO Europe Region there is a widespread lack of drug susceptibility testing capacity to new and re-purposed anti-tuberculosis drugs, lack of access to essential medications in several countries and high treatment cost for drug-resistant tuberculosis.Source: Clinical microbiology and infection [Elektronski vir]. - ISSN 1469-0691 (Vol. 29, iss. 1, Jan. 2023, str. 77-84)Type of material - e-article ; adult, seriousPublish date - 2023Language - englishCOBISS.SI-ID - 119066371
Author
Günther, Gunar |
Guglielmetti, Lorenzo |
Leu, Claude |
Lange, Christoph |
Leth, Frank van
Other authors
Svetina, Petra, 1971-
Topics
Tuberkuloza |
Tuberculosis |
Drug therapy |
Mycobacterium tuberculosis |
Drug therapy |
Health care costs |
Drug therapy |
Tuberkuloza |
Terapija z zdravili |
Mycobacterium tuberculosis |
Terapija z zdravili |
Stroški zdravstvene oskrbe |
Terapija z zdravili |
Europe |
Evropa
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Günther, Gunar | |
Guglielmetti, Lorenzo | |
Leu, Claude | |
Lange, Christoph | |
Leth, Frank van | |
Svetina, Petra, 1971- | 25179 |
Select pickup location:
Material pickup by post
Notification
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.